FDA warns Signature Formulations about contaminated contract-manufactured drug products and cross-contamination at its Phoenix facility.
What happened
FDA inspected Signature Formulations’ Phoenix facility and later obtained and tested lots of its drug products sold in the U.S. Testing found undeclared contamination in all sampled lots, with some results far above the test’s limit of quantitation, and FDA linked the problem to shared equipment and areas. FDA also cited repeated contamination and a prior 2025 recall.
What FDA found
FDA lab testing found undeclared contamination in all sampled lots of the company’s drug products, some far above the test’s limit of quantitation.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The company made these drugs in shared areas and on shared equipment, creating a risk of cross-contamination between products.
FD&C Act section 501(a)(2)(A), 21 U.S.C. 351(a)(2)(A)Residues from one product were not adequately removed by standard cleaning, so shared surfaces and equipment did not prevent contamination.
FD&C Act section 501(a)(2)(A), 21 U.S.C. 351(a)(2)(A)FDA found the quality unit did not have or use enough authority, and management oversight of production and lab operations was not effective.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The company had repeated contamination incidents and a 2025 recall involving its drug products.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
What FDA wants
FDA asks for a written response within 15 business days that includes an inventory and disposition plan for the affected drugs, a commitment not to make products on shared equipment or areas used for the affected products, root-cause investigation and corrective actions, and consideration of a qualified consultant before resuming manufacturing.
Who should pay attention
- brands that contract with this manufacturer
- distributors and retailers selling its drug products
- patients or consumers using the affected products
This is a summary. Read the original letter on fda.gov.